CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM: TWO NOVEL в-LACTAM / β-LACTAMASE INHIBITOR COMBINATION AGENTS FOR THE TREATMENT OF RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS

CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM: TWO NOVEL в-LACTAM / β-LACTAMASE INHIBITOR COMBINATION AGENTS FOR THE TREATMENT OF RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS

Saved in:

Bibliographic Details
Main Authors:	J. L. Liscio, M. V. Mahoney, E. B. Hirsch
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-05-01
Series:	Антибиотики и Химиотерапия
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/639
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Dalia Salem, et al.
Published: (2025-04-01)

Contribution of efflux pump hyperactivity to the resistance to new β-lactam-β-lactamase inhibitor combinations including ceftazidime-avibactam, aztreonam-avibactam, and imipenem-relebactam
by: Sung Pin Tseng, et al.
Published: (2024-12-01)

Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon
by: George F Araj, et al.
Published: (2020-06-01)

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
by: Sunali, et al.
Published: (2025-01-01)

Ceftazidime-Induced Overexpression of MexJK-OprM Confers Resistance to Ceftolozane/Tazobactam in an Isolate of Pseudomonas aeruginosa
by: Sato T, et al.
Published: (2025-08-01)

A Multicenter Retrospective Study on Real-World Outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan
by: Tsung Ying Zegma Yang, et al.
Published: (2024-12-01)

Clinical Eﬃcacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
by: S. V. Yakovlev
Published: (2021-10-01)

Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy
by: Chien Chuang, et al.
Published: (2025-04-01)

Global trends of ceftazidime–avibactam resistance in gram-negative bacteria: systematic review and meta-analysis
by: Yang Wang, et al.
Published: (2025-02-01)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019-01-01)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
by: Jeffrey C. Jolliff, et al.
Published: (2016-01-01)

Mechanisms of ceftolozane/tazobactam resistance in Pseudomonas aeruginosa isolates from South Korea
by: Yu Mi Wi, et al.
Published: (2024-12-01)

A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection
by: Zhang R, et al.
Published: (2025-08-01)

Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples
by: Ravi Kumar Sharma1, et al.
Published: (2023-06-01)

Treatment with Ceftazidime-Avibactam for Lower Respiratory Tract Infections Caused by the Multidrug-Resistant Gram-Negative Bacteria in the Intensive Care Unit
by: Pan J, et al.
Published: (2025-04-01)

Emergence of Tigecycline-Nonsusceptible Carbapenem-Resistant <i>Klebsiella pneumoniae</i> with Metallo-β-Lactamase and Transferable Ceftazidime-Avibactam Resistance in China
by: Yajuan Ni, et al.
Published: (2025-03-01)

In vitro activity of ceftolozane/tazobactam against ESBL-producing enterobacterales in China: SMART 2016–2019
by: Wei Yu, et al.
Published: (2025-05-01)

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa
by: L. M. Saraca, et al.
Published: (2019-01-01)

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01)

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)

PHARMACOKINETICS/PHARMACODYNAMICS OF A 8-LACTAM AND /8-LACTAMASE INHIBITOR COMBINATION: A NOVEL APPROACH FOR AZTREONAM/AVIBACTAM
by: R. .. Singh, et al.
Published: (2020-05-01)

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms
by: María Fernández-Billón, et al.
Published: (2024-12-01)

Genomic Insights into a Multidrug-Resistant Escherichia Coli of sequence type 155: A Ceftazidime-Avibactam Resistant Strain Harboring Four Classes of β-Lactamases
by: Mei Han, et al.
Published: (2025-03-01)

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
by: Angeliki Katsarou, et al.
Published: (2025-02-01)

Antibacterial Activity of Ceftazidime-avibactam against carbapenem-resistant non-fermenters Gram-negative bacteria: a cross-sectional study from a tertiary care hospital
by: Dr Farhan Rasheed
Published: (2025-03-01)

Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA)
by: Alex Soriano, et al.
Published: (2025-03-01)

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae
by: Arun Sachu, et al.
Published: (2025-02-01)

Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
by: Mi Zhou, et al.
Published: (2024-12-01)

Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime–avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulationResearch in context
by: Ivan Alfredo Huespe, et al.
Published: (2025-09-01)

Extended-spectrum β-lactamases genes in Gram-negative isolates from an urban river in Nicaragua
by: C. P. Cabezas-Robelo, et al.
Published: (2025-01-01)

Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital
by: Alessandra Imeneo, et al.
Published: (2025-04-01)

Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia
by: Jessica Matuoka, et al.
Published: (2025-07-01)

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
by: Abolfazl Rafati Zomorodi, et al.
Published: (2025-08-01)

Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children
by: Wilson Toyohiro Hoshino, et al.
Published: (2025-03-01)

Plasmid-mediated β-Lactamases: Nomadic Microbial Assassins Lurking in Multidrug Resistant Gram-negative Strains
by: Christopher M. Connelly, et al.
Published: (2016-11-01)

Metallo-β-Lactamase Producing Gram-Negative Bacteria Isolated from Chicken Meat in Bharatpur, Chitwan
by: Anup Muni Bajracharya, et al.
Published: (2023-11-01)

Evaluation of Adjunctive Aminoglycoside Therapy Compared to β-Lactam Monotherapy in Critically Ill Patients with Gram-Negative Bloodstream Infections
by: Joshua Eudy, et al.
Published: (2025-05-01)

Suitability of Piperacillin–Tazobactam for Treating Dogs Infected with Extended-Spectrum β-Lactamase-Producing Enterobacterales: Pharmacokinetic and Pharmacodynamic Analysis
by: Kazuki Harada, et al.
Published: (2025-04-01)

Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis
by: Natália de Almeida Torres, et al.
Published: (2023-06-01)

Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
by: Ana Kaftandzieva, et al.
Published: (2025-12-01)